Arcus Biosciences, Inc.
RCUS
$10.53
$0.050.48%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 310.26% | -80.69% | -16.13% | 50.00% | 34.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 310.26% | -80.69% | -16.13% | 50.00% | 34.48% |
| Cost of Revenue | 20.87% | 11.93% | 8.60% | 50.00% | 36.90% |
| Gross Profit | 127.63% | -361.11% | -20.97% | -50.00% | -38.18% |
| SG&A Expenses | -3.33% | -12.50% | -3.45% | 0.00% | 7.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.86% | 6.38% | 5.74% | 36.61% | 29.46% |
| Operating Income | 92.45% | -3,150.00% | -13.19% | -31.25% | -27.71% |
| Income Before Tax | 100.00% | -2,700.00% | -16.25% | -33.33% | -25.68% |
| Income Tax Expenses | -- | -- | 0.00% | -- | -- |
| Earnings from Continuing Operations | 100.00% | -2,700.00% | -16.05% | -29.58% | -24.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.00% | -2,700.00% | -16.05% | -29.58% | -24.00% |
| EBIT | 92.45% | -3,150.00% | -13.19% | -31.25% | -27.71% |
| EBITDA | 94.23% | -1,800.00% | -13.64% | -30.38% | -28.40% |
| EPS Basic | -11.49% | -2,353.02% | 5.08% | -5.77% | 0.36% |
| Normalized Basic EPS | 100.00% | -713.28% | 4.92% | -8.82% | -0.98% |
| EPS Diluted | -11.49% | -2,353.02% | 5.08% | -5.77% | 0.36% |
| Normalized Diluted EPS | 100.00% | -713.28% | 4.92% | -8.82% | -0.98% |
| Average Basic Shares Outstanding | 16.47% | 14.15% | 22.27% | 22.52% | 24.45% |
| Average Diluted Shares Outstanding | 16.90% | 14.15% | 22.27% | 22.52% | 24.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |